Literature DB >> 26096091

Assessment of spinal pain.

J Braun1, X Baraliakos2, A Regel2, U Kiltz2.   

Abstract

Spinal pain or back pain is a very common symptom that can have many reasons. The most studied location is low back pain, and it is considered to be nonspecific in the majority of cases. Only a small proportion of patients have axial inflammation as the major cause of their back complaints with chronic inflammatory back pain (IBP) as the most prominent clinical feature of spondyloarthritis (SpA). The recognition of IBP and patients with axial spondyloarthritis (axSpA) is challenging in primary care, and it is important to further facilitate the early diagnosis of SpA. Proposals for improving the referral of patients with a possible diagnosis of axSpA include clinical parameters, human leukocyte antigen (HLA) B27, and imaging parameters. Imaging is crucial for the visualization, objective validation, and understanding of back pain. Numerous diseases such as degenerative disk disease, degenerative changes in the intervertebral (facet) joints and the associated ligaments, spinal instability, herniation of the intervertebral disk, and spinal stenosis have to be differentiated in interpreting imaging of the spine. The sacroiliac joints and the spine are of major importance for the diagnosis and classification of axSpA. Conventional radiographs and magnetic resonance imaging (MRI) are the most important imaging technologies for visualization of structural changes such as syndesmophytes and axial inflammation such as sacroiliitis and spondylitis. The pathogenesis of axSpA is largely genetically determined. HLA B27 has the strongest contribution to the total genetic burden, but other major contributors such as endoplasmic reticulum aminopeptidase (ERAP)-1 and interleukin (IL)-23R have also been identified.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Axial spondyloarthritis; HLA B27; Imaging; Spinal pain

Mesh:

Substances:

Year:  2015        PMID: 26096091     DOI: 10.1016/j.berh.2015.04.031

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  6 in total

Review 1.  [Current treatment of axial spondylarthritis : Clinical efficacy].

Authors:  U Kiltz; J Braun
Journal:  Z Rheumatol       Date:  2020-02       Impact factor: 1.372

2.  Comparison of the short-term effects of the conventional motorized traction with non-surgical spinal decompression performed with a DRX9000 device on pain, functionality, depression, and quality of life in patients with low back pain associated with lumbar disc herniation: A single-blind randomized-controlled trial.

Authors:  Fatmanur Aybala Koçak; Hakan Tunç; Serap Tomruk Sütbeyaz; Selami Akkuş; Belma Füsun Köseoğlu; Ebru Yılmaz
Journal:  Turk J Phys Med Rehabil       Date:  2017-02-16

Review 3.  Mechanisms of low back pain: a guide for diagnosis and therapy.

Authors:  Massimo Allegri; Silvana Montella; Fabiana Salici; Adriana Valente; Maurizio Marchesini; Christian Compagnone; Marco Baciarello; Maria Elena Manferdini; Guido Fanelli
Journal:  F1000Res       Date:  2016-06-28

4.  Sacroiliac Joint Fusion: One Year Clinical and Radiographic Results Following Minimally Invasive Sacroiliac Joint Fusion Surgery.

Authors:  Richard A Kube; Jeffrey M Muir
Journal:  Open Orthop J       Date:  2016-11-30

5.  Influence of Motion Therapy in the Prevention of Lumbar Pain Syndrome Relapse.

Authors:  Eldad Kaljic; Dijana Avdic; Emira Svraka; Mirsad Muftic; Muris Pecar; Amra Macak-Hadziomerovic; Namik Trtak
Journal:  Med Arch       Date:  2018-10

6.  Effects of non-surgical decompression therapy in addition to routine physical therapy on pain, range of motion, endurance, functional disability and quality of life versus routine physical therapy alone in patients with lumbar radiculopathy; a randomized controlled trial.

Authors:  Fareeha Amjad; Mohammad A Mohseni-Bandpei; Syed Amir Gilani; Ashfaq Ahmad; Asif Hanif
Journal:  BMC Musculoskelet Disord       Date:  2022-03-16       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.